Last reviewed · How we verify
JNJ-54135419
At a glance
| Generic name | JNJ-54135419 |
|---|---|
| Also known as | (S)-ketamine |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (PHASE3)
- A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression (PHASE4)
- A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression (PHASE2)
- A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (PHASE3)
- A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression (PHASE1)
- A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine (PHASE1)
- A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants (PHASE1)
- A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-54135419 CI brief — competitive landscape report
- JNJ-54135419 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI